Genetically-Informed RiskProfile for Tobacco Dependence

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Tobacco Dependence+3 More
Genetically-Informed RiskProfile - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new way to help people quit smoking that is tailored to their genetic risk.

Eligible Conditions
  • Tobacco Dependence
  • Tobacco
  • Smoking, Cessation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Tobacco Dependence

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up
Change in perceived benefits of cessation
Change in perceived disease risk
Change in perceived value of cessation treatments
Change in self-efficacy of cessation
Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up
Change in number of cigarettes smoked per day
Change in readiness to quit smoking (Stage of Change)
Change in use of smoking cessation pharmacotherapy in past 30 days
Immediately following intervention receipt
Personal relevance of intervention

Trial Safety

Safety Progress

1 of 3

Other trials for Tobacco Dependence

Trial Design

2 Treatment Groups

Brief Cessation Advice
1 of 2
Genetically-Informed RiskProfile
1 of 2
Active Control
Experimental Treatment

144 Total Participants · 2 Treatment Groups

Primary Treatment: Genetically-Informed RiskProfile · No Placebo Group · N/A

Genetically-Informed RiskProfile
Behavioral
Experimental Group · 1 Intervention: Genetically-Informed RiskProfile · Intervention Types: Behavioral
Brief Cessation Advice
Other
ActiveComparator Group · 1 Intervention: Brief Cessation Advice · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,789 Previous Clinical Trials
2,271,732 Total Patients Enrolled
2 Trials studying Tobacco Dependence
3,195 Patients Enrolled for Tobacco Dependence
National Institute on Drug Abuse (NIDA)NIH
2,225 Previous Clinical Trials
5,612,783 Total Patients Enrolled
19 Trials studying Tobacco Dependence
5,254 Patients Enrolled for Tobacco Dependence
Alex T Ramsey, Ph.D.Principal InvestigatorWashington University School of Medicine

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
I've smoked combustible cigarettes in the past 30 days.
You must be at least 18 years old to buy cigarettes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.